Phase I Study of the CD47 Blocker TTI-621 in Patients with Relapsed or Refractory Hematologic Malignancies.
Stephen M AnsellMichael B MarisAlexander M LesokhinRobert W ChenIan W FlinnAhmed SawasMark D MindenDiego R VillaMary-Elizabeth M PercivalAnjali S AdvaniJames M ForanSteven M HorwitzMatthew G MeiJasmine ZainKerry J SavageChristiane QuerfeldOleg E AkilovLisa D S JohnsonTina CatalanoPenka S PetrovaRobert A UgerEric L SieversAnca MileaKathleen RobergeYaping ShouOwen A O'ConnorPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2021)
TTI-621 was well-tolerated and demonstrated activity as monotherapy in patients with R/R B-NHL and T-NHL and combined with rituximab in patients with R/R B-NHL.